Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:21am, Wednesday, 05'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
12:50pm, Tuesday, 04'th Feb 2025
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
11:00am, Monday, 03'rd Feb 2025
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
03:36pm, Monday, 20'th Jan 2025
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
05:34pm, Wednesday, 15'th Jan 2025
– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Piv
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
10:46am, Monday, 13'th Jan 2025
Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 13'th Jan 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference.
Incyte: Multiple Drug Launches Bode Well For Future Growth
09:30am, Saturday, 11'th Jan 2025
Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually unt
INCY vs. VRTX: Which Stock Is the Better Value Option?
12:51pm, Friday, 10'th Jan 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the bet
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Wednesday, 08'th Jan 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:41pm, Wednesday, 08'th Jan 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 25'th Dec 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investo
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY
07:25am, Thursday, 19'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possibl
